Fate Selling And Marketing Expenses vs Gross Profit Analysis
FATE Stock | USD 4.21 0.01 0.24% |
Fate Therapeutics financial indicator trend analysis is much more than just examining Fate Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fate Therapeutics is a good investment. Please check the relationship between Fate Therapeutics Selling And Marketing Expenses and its Gross Profit accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.
Selling And Marketing Expenses vs Gross Profit
Selling And Marketing Expenses vs Gross Profit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fate Therapeutics Selling And Marketing Expenses account and Gross Profit. At this time, the significance of the direction appears to have weak relationship.
The correlation between Fate Therapeutics' Selling And Marketing Expenses and Gross Profit is 0.34. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Fate Therapeutics, assuming nothing else is changed. The correlation between historical values of Fate Therapeutics' Selling And Marketing Expenses and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Fate Therapeutics are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Selling And Marketing Expenses i.e., Fate Therapeutics' Selling And Marketing Expenses and Gross Profit go up and down completely randomly.
Correlation Coefficient | 0.34 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Selling And Marketing Expenses
Gross Profit
Gross profit is a required income statement account that reflects total revenue of Fate Therapeutics minus its cost of goods sold. It is profit before Fate Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most indicators from Fate Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.The current year's Selling General Administrative is expected to grow to about 85.5 M, whereas Issuance Of Capital Stock is projected to grow to (26.5 K).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 4.5M | 5.8M | 6.7M | 7.1M | Depreciation And Amortization | 1.3M | 13.8M | 18.3M | 19.2M |
Fate Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Fate Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fate Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 302.3M | 622.5M | 921.5M | 705.6M | 506.2M | 310.1M | |
Short Long Term Debt Total | 26.9M | 97.3M | 114.8M | 109.3M | 103.5M | 108.7M | |
Other Current Liab | 17.5M | 54.8M | 45.6M | 57.9M | 27.5M | 18.9M | |
Total Current Liabilities | 27.8M | 85.6M | 81.3M | 114.1M | 39.1M | 36.6M | |
Total Stockholder Equity | 244.8M | 384.4M | 678.8M | 483.9M | 368.4M | 210.3M | |
Other Liab | 4.5M | 58.5M | 52.1M | 3.9M | 4.4M | 4.2M | |
Property Plant And Equipment Net | 22.8M | 67.1M | 70.7M | 66.1M | 158.5M | 166.4M | |
Current Deferred Revenue | 2.8M | 21.1M | 21.5M | 42.2M | 685K | 650.8K | |
Net Debt | (72.9M) | (70.0M) | (18.8M) | 48.0M | 61.7M | 64.7M | |
Retained Earnings | (383.5M) | (556.9M) | (769.1M) | (1.1B) | (1.2B) | (1.2B) | |
Accounts Payable | 5.8M | 6.3M | 8.6M | 8.3M | 4.7M | 4.0M | |
Cash | 99.8M | 167.3M | 133.6M | 61.3M | 41.9M | 39.8M | |
Non Current Assets Total | 75.2M | 128.1M | 288.0M | 203.5M | 174.7M | 183.4M | |
Non Currrent Assets Other | 13.0M | 32.3M | 116.7M | 132.5M | 9.0K | 8.5K | |
Other Assets | 1.6M | 95.8M | 25.1M | 22.5M | 1.0 | 0.95 | |
Cash And Short Term Investments | 221.4M | 482.9M | 615.9M | 436.2M | 315.2M | 224.2M | |
Common Stock Total Equity | 65K | 76K | 88K | 96K | 110.4K | 115.9K | |
Common Stock Shares Outstanding | 68.2M | 82.4M | 94.7M | 96.8M | 98.4M | 54.2M | |
Liabilities And Stockholders Equity | 302.3M | 622.5M | 921.5M | 705.6M | 506.2M | 310.1M | |
Non Current Liabilities Total | 29.7M | 152.4M | 161.3M | 107.6M | 98.7M | 63.3M | |
Other Current Assets | 4.3M | 5.9M | 8.8M | 27.4M | 13.6M | 14.3M | |
Other Stockholder Equity | 628.2M | 941.2M | 1.4B | 1.5B | 1.6B | 1.7B | |
Total Liab | 57.5M | 238.0M | 242.6M | 221.6M | 137.8M | 99.9M | |
Property Plant And Equipment Gross | 34.2M | 99.4M | 70.7M | 66.1M | 206.1M | 216.4M | |
Total Current Assets | 227.1M | 494.3M | 633.4M | 502.1M | 331.5M | 234.9M | |
Accumulated Other Comprehensive Income | 22K | 70K | (762K) | (1.9M) | 15K | 15.8K | |
Short Term Debt | 1.7M | 3.4M | 5.6M | 5.6M | 6.2M | 4.6M | |
Common Stock | 76K | 88K | 96K | 97K | 99K | 58.1K | |
Property Plant Equipment | 11.4M | 32.3M | 162.2M | 176.1M | 202.5M | 212.6M | |
Net Tangible Assets | 274.5M | 536.9M | 678.8M | 483.9M | 556.5M | 584.4M | |
Retained Earnings Total Equity | (285.4M) | (383.5M) | (556.9M) | (769.1M) | (692.2M) | (657.6M) | |
Short Term Investments | 121.6M | 315.6M | 482.3M | 374.9M | 273.3M | 159.4M | |
Capital Surpluse | 445.8M | 628.2M | 941.2M | 1.4B | 1.7B | 1.7B | |
Deferred Long Term Liab | 1.3M | 13.5M | 9.9M | 7.2M | 8.3M | 5.0M | |
Non Current Liabilities Other | 175K | 549K | 702K | 800K | 920K | 721.9K | |
Net Invested Capital | 244.8M | 384.4M | 678.8M | 483.9M | 368.4M | 381.5M |
Fate Therapeutics Investors Sentiment
The influence of Fate Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Fate. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Fate Therapeutics' public news can be used to forecast risks associated with an investment in Fate. The trend in average sentiment can be used to explain how an investor holding Fate can time the market purely based on public headlines and social activities around Fate Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Fate Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Fate Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Fate Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Fate Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Fate Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Fate Therapeutics' short interest history, or implied volatility extrapolated from Fate Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.065 | Quarterly Revenue Growth (0.97) | Return On Assets (0.21) | Return On Equity (0.42) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.